ES2552989T3 - Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina - Google Patents
Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina Download PDFInfo
- Publication number
- ES2552989T3 ES2552989T3 ES12769775.3T ES12769775T ES2552989T3 ES 2552989 T3 ES2552989 T3 ES 2552989T3 ES 12769775 T ES12769775 T ES 12769775T ES 2552989 T3 ES2552989 T3 ES 2552989T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- group
- heterocyclyl
- halogen
- dmso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515165P | 2011-08-04 | 2011-08-04 | |
| US201161515165P | 2011-08-04 | ||
| PCT/US2012/049551 WO2013020062A1 (en) | 2011-08-04 | 2012-08-03 | Quinazoline compounds as serine/threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2552989T3 true ES2552989T3 (es) | 2015-12-03 |
Family
ID=47003195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12769775.3T Active ES2552989T3 (es) | 2011-08-04 | 2012-08-03 | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9187462B2 (enExample) |
| EP (1) | EP2739618B1 (enExample) |
| JP (1) | JP6097289B2 (enExample) |
| KR (1) | KR101979042B1 (enExample) |
| CN (1) | CN103958502B (enExample) |
| BR (1) | BR112014002675A2 (enExample) |
| CA (1) | CA2844058A1 (enExample) |
| ES (1) | ES2552989T3 (enExample) |
| MX (1) | MX340756B (enExample) |
| RU (1) | RU2014108140A (enExample) |
| WO (1) | WO2013020062A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| ES2552989T3 (es) | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| PE20150666A1 (es) | 2012-03-01 | 2015-05-06 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| CA2882750A1 (en) * | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
| EP2909206A1 (en) | 2012-10-16 | 2015-08-26 | F. Hoffmann-La Roche AG | Serine/threonine kinase inhibitors |
| CN103254142B (zh) * | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| EA031243B1 (ru) | 2013-12-06 | 2018-12-28 | Дженентек, Инк. | Ингибиторы серин/треонинкиназ |
| MX375902B (es) | 2013-12-30 | 2025-03-07 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
| KR102379517B1 (ko) * | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| SG11202013175SA (en) | 2018-06-29 | 2021-01-28 | Kinnate Biopharma Inc | Inhibitors of cyclin-dependent kinases |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN115243687A (zh) | 2019-10-25 | 2022-10-25 | 默沙东有限责任公司 | 作为lrrk2抑制剂的n-(杂芳基)喹唑啉-2-胺衍生物、药物组合物及其用途 |
| CN115448864B (zh) * | 2022-08-26 | 2023-12-22 | 上海方予健康医药科技有限公司 | 3-氟-3-（1-羟乙基）吡咯烷-1-羧酸叔丁酯的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| PT672042E (pt) | 1993-10-01 | 2006-08-31 | Novartis Ag | Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CA2274093C (en) | 1996-12-05 | 2006-11-07 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| YU63802A (sh) | 2000-02-25 | 2005-06-10 | F. Hoffmann-La Roche Ag. | Modulatori adenozinskih receptora |
| AU2001252606B2 (en) | 2000-04-26 | 2005-07-07 | Eisai R&D Management Co., Ltd. | Medicinal compositions promoting bowel movement |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| MXPA04011470A (es) | 2002-05-21 | 2005-02-14 | Amgen Inc | Compuestos heterociclicos sustituidos y metodos de uso. |
| WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| KR100799802B1 (ko) * | 2004-02-04 | 2008-01-31 | 화이자 프로덕츠 인크. | 치환된 퀴놀린 화합물 |
| JP2007532669A (ja) | 2004-04-13 | 2007-11-15 | イカジェン インコーポレイテッド | カリウムイオンチャネル調節剤としての多環式ピリミジン |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| CA2578122A1 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Ｅｒｋインヒビターとしてのピロリジン誘導体 |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| CA2661334C (en) | 2006-08-23 | 2011-11-29 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| MX2010005033A (es) | 2007-11-06 | 2010-05-27 | Du Pont | Aminas heterociclicas fungicidas. |
| WO2009146034A2 (en) * | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| WO2009156484A2 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
| PT2370413E (pt) | 2008-12-08 | 2015-10-23 | Arena Pharm Inc | Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo |
| US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| ES2552989T3 (es) | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| PE20150666A1 (es) | 2012-03-01 | 2015-05-06 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| CA2882750A1 (en) | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
-
2012
- 2012-08-03 ES ES12769775.3T patent/ES2552989T3/es active Active
- 2012-08-03 MX MX2014001389A patent/MX340756B/es active IP Right Grant
- 2012-08-03 JP JP2014524111A patent/JP6097289B2/ja active Active
- 2012-08-03 WO PCT/US2012/049551 patent/WO2013020062A1/en not_active Ceased
- 2012-08-03 CA CA2844058A patent/CA2844058A1/en not_active Abandoned
- 2012-08-03 EP EP12769775.3A patent/EP2739618B1/en active Active
- 2012-08-03 US US14/237,143 patent/US9187462B2/en active Active
- 2012-08-03 KR KR1020147005731A patent/KR101979042B1/ko not_active Expired - Fee Related
- 2012-08-03 BR BR112014002675A patent/BR112014002675A2/pt not_active IP Right Cessation
- 2012-08-03 CN CN201280049268.3A patent/CN103958502B/zh active Active
- 2012-08-03 RU RU2014108140/04A patent/RU2014108140A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2739618B1 (en) | 2015-09-16 |
| KR101979042B1 (ko) | 2019-05-15 |
| HK1199248A1 (zh) | 2015-06-26 |
| US9187462B2 (en) | 2015-11-17 |
| JP2014521696A (ja) | 2014-08-28 |
| CN103958502A (zh) | 2014-07-30 |
| JP6097289B2 (ja) | 2017-03-15 |
| WO2013020062A1 (en) | 2013-02-07 |
| RU2014108140A (ru) | 2015-09-10 |
| US20150087664A1 (en) | 2015-03-26 |
| EP2739618A1 (en) | 2014-06-11 |
| HK1199021A1 (zh) | 2015-06-19 |
| BR112014002675A2 (pt) | 2017-02-21 |
| MX340756B (es) | 2016-07-25 |
| MX2014001389A (es) | 2014-11-13 |
| KR20140062057A (ko) | 2014-05-22 |
| CN103958502B (zh) | 2016-02-10 |
| CA2844058A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275649B2 (en) | Irak degraders and uses thereof | |
| KR20240163107A (ko) | 헤테로환 화합물 및 이의 용도 | |
| US20090048429A1 (en) | Processes and intermediates | |
| EP4638457A1 (en) | Heterocycles and uses thereof | |
| JP6378182B2 (ja) | 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤 | |
| JP2021020924A5 (enExample) | ||
| UA117666C2 (uk) | 2-заміщені сполуки цефему | |
| JP2024529126A (ja) | 細胞傷害性標的キメラ | |
| AU2020405536B2 (en) | Benzimidazole derivatives | |
| BR112016004593B1 (pt) | Métodos para reagir um composto, para hidrolisar um composto ou um sal do mesmo, para produzir um composto e para preparar um composto | |
| WO2022100688A1 (zh) | Hpk1激酶调节剂、其制备方法与应用 | |
| CN116783184A (zh) | 含有烷基-氧杂环烷基部分的氨磺酰基脲衍生物及其用途 | |
| TW202440578A (zh) | ２，６，９－三取代嘌呤 | |
| AU2023229518A1 (en) | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | |
| ZA200607634B (en) | Caspase inhibitors and uses thereof | |
| CN113891882B (zh) | 二氢异噁唑的制造方法 | |
| IL283194B1 (en) | Macrolides with 13 members converted to C10-alkylene and their uses | |
| JP2024509437A (ja) | 新規ベンズアゼピン縮合環式誘導体 | |
| WO2025237323A1 (zh) | 噻唑类sting抑制剂及其医药用途 | |
| KR102877899B1 (ko) | Hiv 억제제로서의 신규한 트리테르펜 유도체 | |
| CN114956929A (zh) | 一种手性腈类化合物的合成方法 | |
| Hovey Jr | Development and Application of Carbene Catalysis for Synthesis | |
| TW202440076A (zh) | 阿維菌素衍生物 | |
| WO2025247394A1 (zh) | 含氮杂环化合物、其药物组合物及应用 | |
| El Hilali | Part I: Studies toward the Total Synthesis of Myriaporone 3/4. Part II:(Diisopinocampheyl) borane-Mediated Reductive Aldol Reactions of Allenyl Carboxamides |